Naturalistic Psychedelic Use: A World Apart from Clinical Care
Naturalistic Psychedelic Use: A World Apart from Clinical Care
复制标题
DOI：
10.1080/02791072.2022.2108356
复制
发表时间：
2022-08-13
影响因子：
2.8
通讯作者：
Boehnke, Kevin F.
中科院分区：
文献类型：
--
作者：
Glynos, Nicolas G.;Fields, Christopher W.;Boehnke, Kevin F.
近几十年来，人们对用于治疗目的的致幻剂的兴趣和可用性有所增加。在一项大型匿名在线调查中，我们调查了自然使用致幻剂的人们与医疗保健提供者的沟通模式以及对物质测试套件或服务的认识和利用。样本人群包括迷幻激进主义活动的参与者和迷幻社交媒体论坛的用户。在 1,435 名参与者中，72.5% 的人从未与他们的初级保健提供者 (PCP) 讨论过迷幻剂的使用。只有 4.4% 的人报告在治疗师的帮助下使用迷幻药，3% 的人在临床环境中使用迷幻药，尽管 77.8% 的人非常或极有可能在合法的情况下与治疗师一起服用迷幻药。虽然 62.6% 的参与者了解物质测试服务，但其中 42.6% 的人表示从未使用过这些服务。回归分析确定了与向 PCP 披露和使用物质测试服务相关的几个变量，包括年龄、性别、使用迷幻药的频率和数量，以及在合法可获得的治疗师指导下服用迷幻药的可能性。需要进一步的研究来调查其他群体的这些发现。我们的研究结果表明，需要对医疗保健提供者进行相关培训和教育，以及更明显的物质身份测试选择。
Interest in and availability of psychedelics for therapeutic purposes has increased in recent decades. In a large, anonymous, online survey, we investigated patterns of communication with healthcare providers and awareness and utilization of substance testing kits or services among people using psychedelics naturalistically. The sample population included attendees of a psychedelic activism event and users of psychedelic social media forums. Among 1,435 participants, 72.5% never discussed psychedelic use with their primary care provider (PCP). Only 4.4% reported using psychedelics with a therapist and 3% in clinical settings, although 77.8% were very or extremely likely to take psychedelics with a therapist if one were legally available. While 62.6% of participants were aware of substance testing services, 42.6% of these indicated never using them. Regression analyses identified several variables associated with disclosure to PCP and utilization of substance testing services including age, gender, frequency and number of psychedelics used, and likelihood of consuming psychedelics under the guidance of a therapist if one were legally available. Further research is necessary to investigate these findings among other groups. Our findings suggest that relevant training and education for healthcare providers is needed, along with more visible options for substance identity testing.